Find a Clinical Trial

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.

Gastric Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

  • Details

ClinicalTrials.gov ID: NCT02952534
Diagnosis Type: NA
USOR Number: 16237

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Thyroid Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Head and Neck Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Uterine Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Mesothelioma

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Lymphomas

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

  • Details

ClinicalTrials.gov ID: NCT01897571
Diagnosis Type: Non-Hodgkins
USOR Number: 16248

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Neuroendocrine Tumors

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Vaginal Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Lymphomas

Clinical Trial at: Florida Cancer Affiliates - Ocala

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: NA
USOR Number: 13092

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Breast Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

  • Details

ClinicalTrials.gov ID: NCT02580448
Diagnosis Type: NA
USOR Number: 16010

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Breast Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206)

  • Details

ClinicalTrials.gov ID: NCT02614794
Diagnosis Type: NA
USOR Number: 16195

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Leukemia

Clinical Trial at: Florida Cancer Affiliates - Ocala

(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

  • Details

ClinicalTrials.gov ID: NCT02656303
Diagnosis Type: CLL
USOR Number: 16213

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Lymphomas

Clinical Trial at: Florida Cancer Affiliates - Ocala

SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Hematologic

Clinical Trial at: Florida Cancer Affiliates - Ocala

PNH Registry (M07-001)

  • Details

ClinicalTrials.gov ID: NCT01374360
Diagnosis Type: NA
USOR Number: 08160

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Mesothelioma

Clinical Trial at: Florida Cancer Affiliates - Ocala

Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93)

  • Details

ClinicalTrials.gov ID: NCT01907100
Diagnosis Type: NA
USOR Number: 15175

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Lung Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NA
USOR Number: 15203

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Pages